Aravive, Inc. (ARAV)

Price Chart

Aravive, Inc. (ARAV) stock price: $0.04 (+0.00, +0.00%)

Why Bull

• •Aravive's recent insider buying suggests confidence from those closest to the company, signaling potential future growth. The community sentiment leans towards optimism, fueled by perceived progress in their clinical trials. Positive buzz around potential partnerships is creating excitement among retail investors. Market perception is improving as Aravive gains more visibility within the biotech sector, attracting attention from institutional investors.

Why Bear

• •Despite positive sentiment, concerns linger about Aravive's cash runway and the need for further funding, potentially leading to dilution. The biotech sector is highly competitive, and Aravive faces significant hurdles in achieving regulatory approvals. Negative chatter surfaces occasionally regarding the speed of clinical trial progress and data readouts. Market perception can quickly shift based on news from competitors, creating volatility for Aravive.

• 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  benzinga · Oct 25, 2022
• 52 Biggest Movers From Yesterday
  · Apr 28, 2021
• 38 Stocks Moving In Tuesday's Mid-Day Session
  · Apr 27, 2021
• Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018
  · Dec 20, 2018

Rationale

AI-generated technical analysis for ARAV including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for Aravive, Inc. (ARAV), choose a timeframe, and track your prediction accuracy.

Current price: $0.04

No insider trades in the last 30 days.

Score Factors

• Revenue Growth 5/100

  Revenue growth data is currently unavailable for this company.

• Gross Margin 5/100

  Gross margin data is currently unavailable for this company.

• Operating Leverage 4/100

  Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates ARAV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What does Aravive, Inc. do?

Aravive, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for life-threatening diseases, primarily cancer and fibrosis. Its lead product candidate, batiraxcept, is an ultrahigh-affinity decoy protein that targets the GAS6-AXL signaling pathway, a key driver in tumor growth and resistance. Batiraxcept is currently in Phase III clinical trials for platinum-resistant recurrent ovarian cancer and Phase Ib/II trials for other cancers. The company also develops AVB-S6, a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway. Aravive aims to improve patient outcomes by developing innovative therapies that address unmet medical needs.

Is ARAV stock a good buy?

ARAV stock represents a high-risk, high-reward investment opportunity. The company's future is heavily dependent on the success of batiraxcept in clinical trials and its subsequent regulatory approval. While the Phase III trial in ovarian cancer offers significant potential, clinical trial outcomes are inherently uncertain. The company's negative profit margin and reliance on external funding add to the risk. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in ARAV. Positive data from the Phase III trial could significantly increase the stock's value, while negative results could have a detrimental impact.

What are the main risks for ARAV?

The main risks for Aravive include clinical trial failures, regulatory hurdles, competition from other biotechnology companies, and the need for additional funding. Clinical trial failures for batiraxcept or AVB-S6 would significantly impact the company's value. Regulatory delays or rejection of batiraxcept could also hinder its commercialization. Competition from companies developing similar therapies poses a threat to Aravive's market share. The company's reliance on external funding and high cash burn rate create financial risks. Investors should be aware of these risks before investing in ARAV.

Is ARAV a good stock to buy?

Whether ARAV is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the ARAV MoonshotScore?

The MoonshotScore for ARAV is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is ARAV data updated?

ARAV stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to ARAV is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for ARAV?

Growth catalysts for Aravive, Inc. (ARAV) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Aravive, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are ARAV's main competitors?

Aravive, Inc. (ARAV) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether ARAV has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about ARAV?

Wall Street analyst coverage for ARAV includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is ARAV's market cap?

Market capitalization (market cap) for ARAV is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows ARAV's current market cap alongside enterprise value and other valuation metrics.

How has ARAV stock performed recently?

ARAV's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing ARAV's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in ARAV?

Key risk categories for ARAV include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures ARAV's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling ARAV?

Insider trading activity for ARAV tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is ARAV a good stock for beginners?

Aravive, Inc. (ARAV) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is ARAV for first-time investors?

Every stock carries risk, including Aravive, Inc. (ARAV). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ARAV.